

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigniis 22313-1450

APPLICATION NO. FILING DATE		TILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/485,099		03/02/2001	A. Michael Frace	98,506-C	1471
23859	7590	06/17/2003			
		NBERG P C	EXAMINER		
127 PEACI ATLANTA				LUCAS, ZACHARIAH	
				ART UNIT	PAPER NUMBER
			•	1648 DATE MAILED: 06/17/2003	14

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
•••							
Office Action Summary	09/485,099	FRACE ET AL.					
Onice Action Summary	Examin r	Art Unit					
The MAII INC DATE of this communication and	Zachariah Lucas	1648					
The MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on 27 N							
2a) ☐ This action is FINAL . 2b) ☐ Thi	is action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>24-89</u> is/are pending in the applicatio	n.						
4a) Of the above claim(s) is/are withdray	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.	Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	nim(s) is/are objected to.						
8) Claim(s) 24-89 are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the	•						
11) The proposed drawing correction filed on	,	ved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. ☐ Certified copies of the priority documents have been received.							
Certified copies of the priority documents have been received in Application No							
Copies of the certified copies of the prior application from the International But See the attached detailed Office action for a list of the certified copies of the prior application.	ity documents have been receive reau (PCT Rule 17.2(a)).	ed in this National Stage					
14) Acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. § 119(e	e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)		•					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	r (PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 09/485,099

Art Unit: 1648

DETAILED ACTION

Status of the Claims

- 1. Currently claims 24-60 are pending in the Application. It was noted by the Examiner that the preliminary Amendments filed on September 25, 2001, and February 4, 2000 were entered into the record in reverse order. Upon inquiry by the Examiner, Applicant indicated that the clams submitted in the later filed amendment were those that should be pending in the application. Unfortunately, errors made in the processing of the amendments have prevented the Examiner from correcting the error. In view thereof, it would be appreciated if the Applicant would amend claims 42, 45, 47, 50, 57, and 60 such that they read as indicated in the September 25, 2001 amendment so that the record will clearly reflect the claims as intended by the Applicant.
- 2. While the Examiner has not been able to correct the file record, the below Restriction Requirement/Lack of Unity is drawn in reference to the claims as written in the September 25, 2001 amendment.

Election/Restrictions

3. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Art Unit: 1648

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 24-40 and 65-69, drawn to modified M2 polypeptides, and claims 80-84 drawn to a first method of using the proteins (to determine the presence of anti-M2 antibodies in a subject).

Group II, claim(s) 41-64, drawn to DNA molecules, and to compositions thereof, encoding modifies M2 polypeptides.

Group III, claim(s) 70-74, drawn to antibodies to modified M2 polypeptide, and claims 75-79, drawn to a method of using the antibodies to prevent or treat an influenza A infection.

Group IV, claim(s) 85-89, drawn to a second method of use for the modified M2 polypeptides (to immunize a subject, and thereby produce antibodies.

- 4. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of these Groups relates to a different type of molecules, which performs a different function and has a different structure.
- 5. It is noted that, although Groups I and IV refer to a product and a method of using that product. Under PCT Rule 13.2, the Applicant is entitled to joined or a first method of using a product with the claimed product, but not to a second. As Group IV comprises a second method of use of the modified M2 polypeptides, the claims are not considered part of the same Group.

Conclusion

6. Applicant's attention is hereby directed to the following is a recitation of M.P.E.P. §821.04 regarding the restriction of claims to a product and processes of using the product, Rejoinder:

Where product and process claims drawn to independent and distinct inventions are presented in the same application, applicant may be called upon under 35 U.S.C. 121 to elect claims to either the product or process. See MPEP § 806.05(f) and § 806.05(h). The claims to the nonelected invention will be withdrawn from further consideration under 37 CFR 1.142. See MPEP § 809.02(c) and § 821 through § 821.03. However, if applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims which depend from or otherwise include all the limitations of the allowable product claim will be rejoined.

Application/Control Number: 09/485,099

Art Unit: 1648

Where the application as originally filed discloses the product and the process for making and/or using the product, and only claims directed to the product are presented for examination, when a product claim is found allowable, applicant may present claims directed to the process of making and/or using the patentable product by way of amendment pursuant to 37 CFR 1.121. In view of the rejoinder procedure, and in order to expedite prosecution, applicants are encouraged to present such process claims, preferably as dependent claims, in the application at an early stage of prosecution. Process claims which depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance. Amendments submitted after final rejection are governed by 37 CFR 1.116. Process claims which do not depend from or otherwise include the limitations of the patentable product will be withdrawn from consideration, via an election by original presentation (see MPEP § 821.03). Amendments submitted after allowance are governed by 37 CFR 1.312. Process claims which depend from or otherwise include all the limitations of an allowed product claim and which meet the requirements of 35 U.S.C. 101, 102, 103, and 112 may be entered.

The following is a recitation from paragraph five, "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. §103(b)" (1184 TMOG 86(March 26, 1996)):

"However, in the case of an elected product claim, rejoinder will be permitted when a product claim is found allowable and the withdrawn process claim depends from or otherwise includes all the limitations of an allowed product claim. Withdrawn process claims not commensurate in scope with an allowed product claim will not be rejoined." (emphasis added)

In accordance with M.P.E.P. §821.04 and In re Ochiai, 71 F.3d 1565, 37 USPQ 1127 (Fed. Cir. 1995), rejoinder of product claims with process claims commensurate in scope with the allowed product claims will occur following a finding that the product claims are allowable. Until, such time, a restriction between product claims and process claims is deemed proper. Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution to maintain either dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 09/485,099

Art Unit: 1648

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

8. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Zachariah Lucas whose telephone number is 703-308-4240. The

examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James Housel can be reached on 703-308-4027. The fax phone numbers for the

organization where this application or proceeding is assigned are 703-308-4242 for regular

communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

Z Lucas

Patent Examiner

June 5, 2003

JAMES HOUSEL

SUPERVISORY PATENT EXAMINER

Page 5

TECHNOLOGY CENTER 1600